Title: The Effects of PPAR Agonist Rosiglitazone on Proliferation and Apoptosis in Human Prostate Adenocarcinoma Cell Line LNCAP
Abstract: Objective:To investigate the effects of Rosiglitazone on proliferation and apoptosis of human prostate adenocarcinoma cell line LNCAP in vitro.Methods:After LNCAP cells were treated with ROZ for 24, 48, 72 hours, MTT assay was used to detect the changes in growth LNCAP.LNCAP cell apoptosis was evaluated by flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling(TUNEL).The expression levels of Caspase-3 were examined in LNCAP cells by Western Blot.Results:ROZ signifi-cantly inhibited cell growth of LNCAP cells.At the concentration of 100 mol/L, ROZ showed a high inhibitory rate of 78.58 % after 72 h treatment.Flow cytomewtry showed a significant increase in the number of apoptosis cells, and it reached 48.11 % after ROZ(100 mol/L) treatment for 72 h.At the same time, TUNEL staining positive cells significantly increased in ROZ treated group compared to the control.Western Blot showed that ROZ enhanced the expression of Caspase-3, a critical protein inducing cell apoptosis.Conclusions:Rosiglitazone inhibits cell growth of human prostate adenocarcinoma cell line LNCAP by inducing cell apoptosis in vitro.ROZ might become a new drug to treat patients with prostate cancer.
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot